IDEXX Laboratories IDXX
IDEXX Laboratories is a veterinary diagnostics company offering instruments, reagents, and software for clinics, with a recurring revenue model from consumables and diagnostic services. IDEXX maintains a solid moat with ROIC of 58.8% and operating margin of 35%, but its demanding valuation (P/E 36.5, PEG 2.84) and negative momentum (-12.2% over 12 months) limit short-term appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
IDEXX Laboratories is a veterinary diagnostics company offering instruments, reagents, and software for clinics, with a recurring revenue model from consumables and diagnostic services. IDEXX maintains a solid moat with ROIC of 58.8% and operating margin of 35%, but its demanding valuation (P/E 36.5, PEG 2.84) and negative momentum (-12.2% over 12 months) limit short-term appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.8 |
| Quality / Moat | 8.9 |
| Valuation | 3.0 |
| Growth | 6.9 |
| Dividend | 1.5 |
| Momentum | 2.0 |
| Risk & Context | 3.8 |
OVERALL SCORE: 5.5/10
Context and risks
No material exposure to current macro factors: the veterinary diagnostics business does not depend on oil, interest rates affect it only via valuation (already captured by the model with P/E 36.5), and there is no relevant specific geopolitical or regulatory risk.
News considered in the analysis
- Should You Continue to Hold IDXX Stock in Your Portfolio? — Artículo de opinión genérico de Zacks sin información nueva sobre la empresa.
- IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets — Reafirmación de objetivos de crecimiento a largo plazo en conferencia con analistas; refuerza la visibilidad del negocio pero no es un evento material nuevo.
- IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference — Presentación de impulsores de crecimiento (test de cáncer) en conferencia; positivo para la narrativa de crecimiento, sin impacto cuantificable inmediato.
- IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics — Iniciativa de IA para mejorar la adopción de diagnósticos; potencial positivo pero aún en fase temprana y sin resultados medibles.
- IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide — Análisis de valoración de Simply Wall St; opinión sin información nueva sobre fundamentales.
Verdict: Hold: exceptional quality and stable growth, but wait for a better entry point given the elevated multiple and weak price trend.
Main risk: The demanding valuation (P/E 36.5) leaves little room for error: any slowdown in the 9.7% revenue growth could compress the multiple significantly.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →